ReviewAmerican journal of hematology2012
von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.
Review in American journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- Association of Organ Preservation Methods With Von Willebrand Factor Upregulation in Microvascular Endothelial Cells Posttransplantation: Ex Vivo Lung Perfusion and Static Cold Storage.Transplantation direct · 2026Article
- High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.International journal of hematology · 2023Article
- Article
- Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis.Frontiers in immunology · 2020Article
- Unraveling the effect of silent, intronic and missense mutations onHaematologica · 2019Article
- Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.British journal of haematology · 2018Article
- A case report on the successful perioperative management of hepatectomy for hepatocellular carcinoma in a patient with von Willebrand disease.International journal of surgery case reports · 2018Article
- Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin.Oncotarget · 2017Article
- [Detection and analysis of plasma VWF levels in healthy Chinese by automatic standardized assay].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Article
- Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2016Article
- Article
- The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.British journal of haematology · 2014Review
- Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.Blood · 2013Article
- On the versatility of von Willebrand factor.Mediterranean journal of hematology and infectious diseases · 2013Article
- Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.Mediterranean journal of hematology and infectious diseases · 2013Article
- How much medicine do spine surgeons need to know to better select and care for patients?Surgical neurology international · 2012Article
- Preoperative diagnosis and management of inherited bleeding disorders in female adolescents and adults.Canadian journal of surgery. Journal canadien de chirurgieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
During the past 25 years, our knowledge concerning the pathogenesis, diagnostic strategies, and treatment of von Willebrand disease (VWD) has increased significantly. Following the immunological differentiation of factor VIII (FVIII) and von Willebrand factor (VWF) in the 1970s and the cloning of the FVIII and VWF genes in the mid-1980s, substantial progress has been made in our understanding of this, the most common inherited bleeding disorder. We now recognize that VWD represents a range of genetic diseases all with the clinical endpoint of increased mucocutaneous bleeding. The molecular pathology of Type 2 and 3 VWD is now comprehensively documented and involves rare sequence variants at the VWF locus. In contrast, the genetic causation of Type 1 disease remains incompletely defined and in many cases appears to involve genetic determinants in addition to or instead of VWF. The diagnostic triad of a personal history of excessive mucocutaneous bleeding, laboratory tests for VWF that are consistent with VWD, and a family history of the condition remain the keystone to VWD identification. In the laboratory, measurement of VWF antigen and function continue to be the most important diagnostic studies, and while our understanding of the molecular genetic pathology of VWD has advanced considerably in the past decade, genetic testing as a component of diagnosis is limited to certain distinct subtypes of the disorder. Treatment of VWD has been relatively unchanged for the past decade and continues to involve either stimulation of the release of intrinsic VWF with desmopressin or the infusion of VWF concentrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.